How semaglutide is administered: injections, the new tablet, and how to choose

The injection route: what actually happens each week

Wegovy (the injectable form) is given once a week, on the same day each week, as a subcutaneous injection, meaning the needle goes just under the skin, not into muscle. The pre-filled pen makes this simpler than it sounds. You choose a site: the soft area around your abdomen (at least a few centimetres from the navel), the front or outer thigh, or the upper arm. Each time you inject, you rotate to a different spot within that zone so the tissue gets a rest.

The pen is held against the skin, the button is pressed, and the injection takes a few seconds. Most people describe a mild sting or nothing at all. Redness or a small bump at the site can occur and usually fades quickly. Full step-by-step technique is covered in the patient information leaflet that comes with your pen, and our detailed guide to administering Wegovy walks through it in plain language. If you prefer to see it done, a video walkthrough is also available.

The pen is stored in the fridge between 2°C and 8°C. There is a limited window during which a pen can be kept at room temperature, the exact duration is printed in your leaflet, and that figure is the one to follow, not any number you read online. Timing matters: many people find it easier to pick a consistent day, such as a Monday morning, so it becomes habit rather than a thing to remember.

The tablet route: a newer decision to weigh up

If injections feel like a barrier (and for some people they genuinely are) the Wegovy tablet offers a real alternative. It was approved by the MHRA on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 for weight management. The dose escalation runs from 1.5mg through 4mg and 9mg to a 25mg daily maintenance dose, with at least a month at each level.

The administration requirement is specific. The tablet is taken first thing in the morning, before any food or drink other than a small amount of plain water (around 120ml), and you wait at least 30 minutes before eating, drinking coffee, or taking other oral medicines. Swallow it whole. This matters because the absorption enhancer the tablet relies on is sensitive to food and other liquids, getting the timing right is part of how the medicine works. The practical upside is significant: no refrigeration, no disposal of sharps, straightforward when travelling.

In the OASIS 4 trial (307 adults over 64 weeks), participants on the tablet lost around 13.6% of their body weight on average compared with around 2.4% on placebo. Among those who followed the regimen fully, the average reached approximately 17%. Clinical trial evidence like this is always an average across a study population; individual responses vary, and a prescriber is the right person to help you interpret what it might mean for you.

Which route is right for you, and how the decision gets made

This is where the SK3 frame becomes honest: there is not a single correct answer, and the decision is not yours to make alone. It belongs in a clinical conversation. A few things tend to shape it.

Needle aversion is real and worth stating plainly in your consultation rather than pushing through it. The tablet removes that barrier entirely. On the other hand, timing the injection is more forgiving than timing the tablet, the weekly injection can move by a day or two if needed, whereas the tablet's morning-fast protocol is fixed and daily. People with complex morning routines, early commutes, or shared households sometimes find the weekly injection easier to fit around life once they get used to it.

There are also clinical considerations your prescriber will weigh: certain gastrointestinal conditions, other medicines you take, and your medical history can influence which route is appropriate. For context on how semaglutide works in the body and what the wider treatment picture looks like, our semaglutide overview covers the mechanism, evidence, and eligibility criteria in detail. A fuller look at the Wegovy-specific picture (including the Wegovy treatment page) is a useful read before deciding.

If you are already established on the 2.4mg weekly injection and considering switching, that transition requires prescriber input too; the tablet's maintenance dose and the injection's maintenance dose are not interchangeable steps, and the clinical guidance is clear that any switch needs assessment.

What prescription access actually looks like in the UK

Semaglutide for weight management is a prescription-only medicine. That is not a formality, it reflects real clinical considerations around eligibility, contraindications (pregnancy, certain gastrointestinal conditions, a history of specific thyroid tumours), and ongoing monitoring. The NHS England guidance on weight-management injections sets out the clinical framework that prescribers work within.

On the NHS, access follows strict phased criteria and typically involves specialist weight management services with waiting lists. Privately, through a regulated online pharmacy, the route is faster, but the clinical rigour should be identical. Any legitimate service will require a proper consultation, identity verification, and a prescriber's sign-off before dispensing. If you want to understand how private access compares and what the process involves, the Wegovy sourcing guide covers the landscape honestly. Semaglutide is not a medicine to source from an unverified seller, and the MHRA has been clear about the risks of counterfeit pens sold online without a genuine clinical assessment behind them.

At nume, a named GPhC-registered prescriber reads your consultation the same day, not software, not a triage bot. If you are clinically suitable, our pharmacy dispatches the same day you are approved, with free next-working-day delivery in plain packaging. Check your eligibility by starting your free consultation at our treatment page.